EL · Insider Trading
The Estee Lauder Companies Inc. Class A
Every open-market purchase and sale reported by EL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-16 | Jennifer Tejada | Director | A | +16 deriv. | — |
| 2026-09-16 | Charlene Barshefsky | Director | A | +86 deriv. | — |
| 2026-09-16 | Annabelle Yu Long | Director | A | +2 deriv. | — |
| 2026-09-16 | Jennifer Hyman | Director | A | +16 deriv. | — |
| 2026-09-16 | Paul J Fribourg | Director | A | +205 deriv. | — |
| 2026-09-16 | Eric Louis Zinterhofer | Director | A | +18 deriv. | — |
| 2026-09-16 | Barry S Sternlicht | Director | A | +242 deriv. | — |
| 2026-09-16 | Dana Strong | Director | A | +2 deriv. | — |
| 2026-09-16 | William P Lauder | Director | A | +2 deriv. | — |
| 2026-09-16 | Jane Lauder | Director | A | +2 deriv. | — |
| 2026-09-16 | Gary M Lauder | Director | A | +16 deriv. | — |
| 2026-09-16 | Arturo Nunez | Director | A | +15 deriv. | — |
| 2026-09-16 | Richard F Zannino | Director | A | +49 deriv. | — |
| 2026-09-15 | Paul J Fribourg | Director | Sell | −103,000 | −$10.05M |
| 2026-09-10 | Charlene Barshefsky | Director | MIXED | +922 | −$4.99K |
| 2026-08-31 | Meridith Webster | Exec VP GlobalComm/PubAffairs | A | +24,486 deriv. | — |
| 2026-08-31 | Hendrik Rene Lammers | EVP & CR&IO | A | +46,145 deriv. | — |
| 2026-08-31 | Roberto Canevari | Exec VP & CVCO | A | +41,189 deriv. | — |
| 2026-08-31 | Hudis Jane Hertzmark | Exec VP & CBO | A | +77,935 deriv. | — |
| 2026-08-31 | Akhil Shrivastava | Exec VP & CFO | A | +47,222 deriv. | — |
| 2026-08-31 | Faverie Stephane de la | President and CEO | A | +174,899 deriv. | — |
| 2026-08-31 | Michael Bowes | Exec VP & CPO | A | +22,737 deriv. | — |
| 2026-08-31 | Rashida La Lande | Exec VP & General Counsel | MIXED | — | −$1.50M |
| 2026-08-25 | Rashida La Lande | Exec VP & General Counsel | MIXED | — | −$37.17K |
| 2026-08-24 | Richard F Zannino | Director | M | +4,697 | +$368.06K |
| 2026-07-22 | Barry S Sternlicht | Director | A | +327 deriv. | — |
| 2026-07-22 | Paul J Fribourg | Director | A | +409 deriv. | — |
| 2026-07-22 | Eric Louis Zinterhofer | Director | A | +327 deriv. | — |
| 2026-06-16 | Annabelle Yu Long | Director | A | +3 deriv. | — |
| 2026-06-16 | Paul J Fribourg | Director | A | +217 deriv. | — |
| 2026-06-16 | Dana Strong | Director | A | +3 deriv. | — |
| 2026-06-16 | Barry S Sternlicht | Director | A | +256 deriv. | — |
| 2026-06-16 | Arturo Nunez | Director | A | +16 deriv. | — |
| 2026-06-16 | Gary M Lauder | Director | A | +17 deriv. | — |
| 2026-06-16 | Richard F Zannino | Director | A | +53 deriv. | — |
| 2026-06-16 | Charlene Barshefsky | Director | A | +91 deriv. | — |
| 2026-06-16 | Eric Louis Zinterhofer | Director | A | +18 deriv. | — |
| 2026-06-16 | Jane Lauder | Director | A | +3 deriv. | — |
| 2026-06-16 | Jennifer Hyman | Director | A | +17 deriv. | — |
| 2026-06-16 | William P Lauder | Director | A | +3 deriv. | — |
| 2026-06-16 | Jennifer Tejada | Director | A | +17 deriv. | — |
| 2026-05-18 | Barry S Sternlicht | Director | A | +336 deriv. | — |
| 2026-05-18 | Eric Louis Zinterhofer | Director | A | +336 deriv. | — |
| 2026-05-18 | Paul J Fribourg | Director | A | +420 deriv. | — |
| 2026-04-10 | Ronald S Lauder | Chairman, Clinique Labs, LLC | G | −4,768,846 deriv. | — |
| 2026-04-10 | Aerin Lauder | 10%+ Owner | G | +4,768,846 deriv. | — |
| 2026-03-17 | Dana Strong | Director | A | +3 deriv. | — |
| 2026-03-17 | Jennifer Tejada | Director | A | +17 deriv. | — |
| 2026-03-17 | Richard F Zannino | Director | A | +53 deriv. | — |
| 2026-03-17 | Charlene Barshefsky | Director | A | +92 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gary M Lauder | Director | 774,124 | $73.12M |
| Ronald S Lauder | Chairman, Clinique Labs, LLC | 706,364 | $66.72M |
| Paul J Fribourg | Director | 464,523 | $43.87M |
| Fabrizio Freda | President and CEO | 295,838 | $27.94M |
| Jane Lauder | Director | 58,763 | $5.55M |
| Barry S Sternlicht | Director | 46,812 | $4.42M |
| Charlene Barshefsky | Director | 29,950 | $2.83M |
| William P Lauder | Director | 27,773 | $2.62M |
| Hudis Jane Hertzmark | Exec VP & CBO | 27,385 | $2.59M |
| Faverie Stephane de la | President and CEO | 20,963 | $1.98M |
| Richard F Zannino | Director | 16,856 | $1.59M |
| Lynn Forester | Director | 15,479 | $1.46M |
| Leonard A. Lauder 2013 Revocable Trust | 10%+ Owner | 15,000 | $1.42M |
| Michael O'Hare | EVP-Global Human Resources | 13,045 | $1.23M |
| Carl P. Haney | EVP Research Prod & Innovation | 11,847 | $1.12M |
| Roberto Canevari | Exec VP & CVCO | 10,403 | $982.56K |
| Akhil Shrivastava | Exec VP & CFO | 10,034 | $947.73K |
| Rashida La Lande | Exec VP & General Counsel | 7,766 | $733.50K |
| Peter Jueptner | Group President | 7,354 | $694.60K |
| Richard D Parsons | Director | 3,042 | $287.32K |
| Jennifer Hyman | Director | 2,350 | $221.96K |
| Michael Bowes | Exec VP & CPO | 2,348 | $221.86K |
| Jennifer Tejada | Director | 2,000 | $188.90K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the EL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.